• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Concordance and Discordance Rates of V-Raf Murine Sarcoma Viral Oncogene Homolog B1 () Status in Metastatic against Primary Lesion of Melanoma: A Meta-analysis.

作者信息

Yokomichi Hiroshi, Inozume Takashi, Wada Makoto, Asai Jun, Igaki Hiroshi, Namikawa Kenjiro, Hayashi Ayato, Fukushima Satoshi, Fujimura Taku, Koga Hiroshi, Nakamura Yasuhiro, Mochizuki Mie, Yamagata Zentaro

机构信息

Department of Health Sciences, University of Yamanashi, Chuo, Japan.

Department of Dermatology, University of Yamanashi, Chuo, Japan.

出版信息

JMA J. 2020 Jul 15;3(3):274-279. doi: 10.31662/jmaj.2020-0016. Epub 2020 Jul 7.

DOI:10.31662/jmaj.2020-0016
PMID:33150263
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7590371/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40c9/7590371/9412b994a395/2433-3298-3-3-0274-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40c9/7590371/3a8c829fb965/2433-3298-3-3-0274-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40c9/7590371/7df4a04f51a1/2433-3298-3-3-0274-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40c9/7590371/9412b994a395/2433-3298-3-3-0274-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40c9/7590371/3a8c829fb965/2433-3298-3-3-0274-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40c9/7590371/7df4a04f51a1/2433-3298-3-3-0274-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40c9/7590371/9412b994a395/2433-3298-3-3-0274-g003.jpg

相似文献

1
Concordance and Discordance Rates of V-Raf Murine Sarcoma Viral Oncogene Homolog B1 () Status in Metastatic against Primary Lesion of Melanoma: A Meta-analysis.黑色素瘤转移灶与原发灶中V-Raf鼠肉瘤病毒癌基因同源物B1（）状态的一致性和不一致率：一项荟萃分析。
JMA J. 2020 Jul 15;3(3):274-279. doi: 10.31662/jmaj.2020-0016. Epub 2020 Jul 7.
2
Effects of Copper Chelation on BRAF Positive Colon Carcinoma Cells.铜螯合对BRAF阳性结肠癌细胞的影响。
Cancers (Basel). 2019 May 12;11(5):659. doi: 10.3390/cancers11050659.
3
Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.棉花素作为一种新型的 V-RAF 鼠肉瘤病毒致癌基因同源物 B1 和细胞周期蛋白依赖性激酶 4 的选择性双重抑制剂用于治疗黑色素瘤。
Mol Cancer Ther. 2013 Apr;12(4):361-72. doi: 10.1158/1535-7163.MCT-12-0965. Epub 2013 Mar 29.
4
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.应用突变特异性单克隆抗体的免疫组织化学法检测 BRAF V600E 突变状态。
Acta Neuropathol. 2011 Jul;122(1):11-9. doi: 10.1007/s00401-011-0841-z. Epub 2011 Jun 3.
5
Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold.基于2,6-二取代吡嗪支架的v-raf鼠肉瘤病毒癌基因同源物B1（BRAF）新型抑制剂。
J Med Chem. 2008 Jun 12;51(11):3261-74. doi: 10.1021/jm070776b. Epub 2008 May 13.
6
Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma.黑色素瘤中BRAF V600E突变的前瞻性免疫组织化学分析
Hum Pathol. 2015 Feb;46(2):169-75. doi: 10.1016/j.humpath.2014.08.018. Epub 2014 Oct 30.
7
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.新型RAF抑制剂GDC-0879的抗肿瘤疗效可通过BRAFV600E突变状态和细胞外信号调节激酶/丝裂原活化蛋白激酶途径的持续抑制来预测。
Cancer Res. 2009 Apr 1;69(7):3042-51. doi: 10.1158/0008-5472.CAN-08-3563. Epub 2009 Mar 10.
8
[Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma].[成釉细胞瘤中v-raf鼠肉瘤病毒癌基因同源物基因突变的研究进展]
Zhonghua Kou Qiang Yi Xue Za Zhi. 2018 Jul 9;53(7):500-502. doi: 10.3760/cma.j.issn.1002-0098.2018.07.016.
9
Pharmacokinetic Evaluation of [C]CEP-32496 in Nude Mice Bearing BRAF Mutation-Induced Melanomas.携带BRAF突变诱导黑色素瘤的裸鼠中[C]CEP - 32496的药代动力学评估
Mol Imaging. 2018 Jan-Dec;17:1536012118795952. doi: 10.1177/1536012118795952.
10
Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases.一名伴有骨髓转移的黑色素瘤患者中，Cobas BRAF V600检测与VE1免疫组化结果的不一致性
Am J Dermatopathol. 2016 Sep;38(9):687-9. doi: 10.1097/DAD.0000000000000660.

本文引用的文献

1
Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019.日本皮肤病学会指南：2019 年皮肤黑色素瘤指南概要。
J Dermatol. 2020 Feb;47(2):89-103. doi: 10.1111/1346-8138.15151. Epub 2019 Nov 28.
2
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.达拉非尼联合曲美替尼治疗转移性黑色素瘤的 5 年结果。
N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4.
3
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine.
进行 BRAF 基因突变的分子检测以辅助黑色素瘤治疗决策：向精准医疗迈进。
Mod Pathol. 2018 Jan;31(1):24-38. doi: 10.1038/modpathol.2017.104. Epub 2017 Nov 17.
4
Somatic mutation analysis in melanoma using targeted next generation sequencing.利用靶向新一代测序技术进行黑色素瘤的体细胞突变分析。
Exp Mol Pathol. 2017 Oct;103(2):172-177. doi: 10.1016/j.yexmp.2017.08.006. Epub 2017 Aug 16.
5
Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis.转移性恶性黑色素瘤患者 BRAF 状态的差异：一项荟萃分析。
Eur J Cancer. 2017 Aug;81:106-115. doi: 10.1016/j.ejca.2017.05.015. Epub 2017 Jun 15.
6
Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.日本一家机构原发性和转移性黑色素瘤驱动基因突变的比较研究：肿瘤内和肿瘤间异质性的线索
J Dermatol Sci. 2017 Jan;85(1):51-57. doi: 10.1016/j.jdermsci.2016.10.006. Epub 2016 Oct 13.
7
BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.原发性和转移性黑色素瘤中BRAF-V600突变的异质性：焦磷酸测序和免疫组织化学研究
Am J Dermatopathol. 2016 Feb;38(2):113-20. doi: 10.1097/DAD.0000000000000404.
8
Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.原发性黑色素瘤及配对转移灶中BRAFV600突变的等位基因频率及其与转移性黑色素瘤BRAF抑制剂治疗的相关性。
Oncotarget. 2015 Nov 10;6(35):37895-905. doi: 10.18632/oncotarget.5634.
9
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.日本黑色素瘤患者中与BRAF、NRAS和KIT突变相关的临床特征。
J Dermatol Sci. 2015 Oct;80(1):33-7. doi: 10.1016/j.jdermsci.2015.07.012. Epub 2015 Jul 26.
10
BRAF mutation screening in melanoma: is sentinel lymph node reliable?黑色素瘤中的BRAF突变筛查：前哨淋巴结是否可靠？
Melanoma Res. 2015 Aug;25(4):328-34. doi: 10.1097/CMR.0000000000000166.